Palomino Laboratories (PALX) Cash & Equivalents (2022 - 2025)

Palomino Laboratories (PALX) has 4 years of Cash & Equivalents data on file, last reported at $8.1 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 5931.21% year-over-year to $8.1 million; the trailing twelve-month figure through Dec 2025 stood at $8.1 million (up 5931.21% YoY), and the FY2025 full-year result was $8.1 million, up 5931.21% from the prior year.
• Cash & Equivalents rose to $8.1 million in Q4 2025, from $7.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $8.1 million in Q4 2025 to a low of $322.0 in Q2 2024.
• A 4-year average of $1.5 million and a median of $500.0 in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents dropped 24.0% in 2023 and soared 2452250.62% in 2025, its largest moves.
• Tracing PALX's Cash & Equivalents over 4 years: stood at $500.0 in 2022, then retreated by 24.0% to $380.0 in 2023, then jumped by 35336.05% to $134657.0 in 2024, then jumped by 5931.21% to $8.1 million in 2025.
• Business Quant data shows PALX's Cash & Equivalents at $8.1 million in Q4 2025, $7.9 million in Q3 2025, and $1887.0 in Q2 2025.